RT Journal Article
T1 The melatonergic agonist agomelatine ameliorates high fat diet-induced obesity in mice through the modulation of the gut microbiome.
A1 Diez-Echave, Patricia
A1 Vezza, Teresa
A1 Algieri, Francesca
A1 Ruiz-Malagon, Antonio Jesús
A1 Hidalgo-Garcia, Laura
A1 Garcia, Federico
A1 Moron, Rocio
A1 Sanchez, Manuel
A1 Toral, Marta
A1 Romero, Miguel
A1 Duarte, Juan
A1 Garrido-Mesa, Jose
A1 Rodriguez-Cabezas, Maria Elena
A1 Rodriguez-Nogales, Alba
A1 Galvez, Julio
K1 Agomelatine
K1 Melatonin
K1 Metabolism
K1 Metformin
K1 Microbiome
K1 Obesity
AB Melatonin has shown beneficial effects on obesity, both in humans and experimental models, via regulating the altered circadian rhythm and thus ameliorating the gut dysbiosis associated with this metabolic condition. However, its clinical use is limited, mostly due to its short half-life. Agomelatine is an agonist of the melatonin receptors that could be used to manage obesity and offer a better profile than melatonin. Male C57BL/6 mice were fed a high fat diet and orally treated for five weeks with agomelatine, or melatonin or metformin, used as control drugs. Metabolic profile, inflammatory status, vascular dysfunction and intestinal microbiota composition were assessed. Agomelatine lessened body weight gain, enhanced glucose and lipid metabolisms, and improved insulin resistance. It also reduced the obesity-associated inflammatory status and endothelial dysfunction, probably linked to its effect on gut dysbiosis, consisting of the restoration of bacterial populations with key functions, such as short chain fatty acid production. Agomelatine can be considered as a novel therapeutic tool for the management of human obesity and its associated comorbidities.
PB Elsevier Masson
YR 2022
FD 2022-07-18
LK http://hdl.handle.net/10668/22045
UL http://hdl.handle.net/10668/22045
LA en
NO Diez-Echave P, Vezza T, Algieri F, Ruiz-Malagón AJ, Hidalgo-García L, García F, et al. The melatonergic agonist agomelatine ameliorates high fat diet-induced obesity in mice through the modulation of the gut microbiome. Biomed Pharmacother. 2022 Sep;153:113445.
NO This work was supported by the Junta de Andalucía (CTS 164) and by Instituto de Salud Carlos III (PI19/01058) with funds from the European Union. T. Vezza is a postdoctoral fellow from Instituto de Investigación Biosanitaria de Granada; P. Diez-Echave, F. Algieri and J. Garrido-Mesa are postdoctoral fellows from University of Granada; A.J. Ruiz-Malagón and L. Hidalgo-García are predoctoral fellows from University of Granada (“Programa de Doctorado: Medicina Clínica y Salud Pública”). CIBER-EHD, CIBERCV and “Red de Investigación en SIDA” are supported by Instituto de Salud Carlos III.
DS RISalud
RD Apr 7, 2025